Compare SLE & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | ENSC |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.1M |
| IPO Year | 2019 | N/A |
| Metric | SLE | ENSC |
|---|---|---|
| Price | $0.51 | $0.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 262.2K | 119.4K |
| Earning Date | 11-13-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,568,000.00 | $4,487,973.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.51 |
| 52 Week Low | $0.53 | $0.76 |
| 52 Week High | $26.00 | $8.97 |
| Indicator | SLE | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 37.65 |
| Support Level | $0.62 | $0.76 |
| Resistance Level | $0.76 | $0.95 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 9.11 | 47.80 |
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.